145,092 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Acquired by Norges Bank

Norges Bank acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 145,092 shares of the biopharmaceutical company's stock, valued at approximately $4,768,000. Norges Bank owned approximately 0.25% of Agios Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. KBC Group NV lifted its position in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares in the last quarter. Atria Investments Inc raised its stake in shares of Agios Pharmaceuticals by 6.9% in the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock worth $373,000 after purchasing an additional 737 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $33,000. Swiss National Bank boosted its position in shares of Agios Pharmaceuticals by 1.0% during the fourth quarter. Swiss National Bank now owns 100,760 shares of the biopharmaceutical company's stock valued at $3,311,000 after buying an additional 1,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Agios Pharmaceuticals by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,092 shares of the biopharmaceutical company's stock worth $397,000 after buying an additional 1,150 shares in the last quarter.

Remove Ads

Analyst Ratings Changes

Several equities analysts have weighed in on AGIO shares. StockNews.com cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of "Hold" and a consensus target price of $56.57.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded up $0.22 on Tuesday, reaching $27.74. 140,904 shares of the company traded hands, compared to its average volume of 708,411. The company has a 50 day moving average of $31.25 and a 200 day moving average of $39.06. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The firm has a market capitalization of $1.59 billion, a PE ratio of 2.44 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.